
Pfizer (PFE) Stock Forecast & Price Target
Pfizer (PFE) Analyst Ratings
Bulls say
Pfizer is a global biopharmaceutical company with a strong focus on developing and selling prescription drugs and vaccines, with international sales being a major contributor to their revenue. Their recent acquisition of Metsera adds potential for growth in the obesity market and their strong infrastructure and commercial expertise should allow them to advance the Metsera portfolio rapidly and reach its full potential. Furthermore, positive bioavailability and food-effect data from their oral programs could be impactful catalysts that validate the platform's differentiation and expand the addressable market opportunity.
Bears say
Pfizer is facing several headwinds in the near term with challenges to its key patents in the cardiovascular and vaccine market. Additionally, the company is facing risks in terms of new growth drivers, with potential negative trial results for its pipeline drugs. Furthermore, Pfizer's reputation and potential access to emerging markets could be negatively affected by ongoing controversies surrounding COVID-19 vaccines.
This aggregate rating is based on analysts' research of Pfizer and is not a guaranteed prediction by Public.com or investment advice.
Pfizer (PFE) Analyst Forecast & Price Prediction
Start investing in Pfizer (PFE)
Order type
Buy in
Order amount
Est. shares
0 shares